Compare Amgen, Inc. (AMGN) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Palantir Technologies Inc — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Palantir Technologies Inc trades at $127.3 (market cap $303.96B). The key difference: Palantir Technologies Inc is the larger of the two by market cap, and Amgen, Inc. pays a 2.77% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| AMGN | PLTR | |
|---|---|---|
Market Cap | $196.12B | $303.96B |
Sector | Health | Technology |
52-Week High | $388.16 | $207.18 |
52-Week Low | $271.18 | $107.27 |
Enterprise Value | $241.41B | $296.14B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PLTR trades at $126.79, down 1.74% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported strong fundamentals, with Q1 2026 EPS of $0.33 beating expectations, revenue growth accelerating to 85% YoY, and a net income margin of 43.67%. Recent news highlights CEO commentary on AI competition and robust U.S. revenue expansion of 104%.
The outlook remains positive given earnings beats and growth trajectory, but high valuation multiples (P/E 142.46) pose a risk if growth slows. Analyst consensus price target is $185.67, suggesting upside, though bearish technicals and sector volatility warrant caution for near-term entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
